David Davidson Sells 6,000 Shares of bluebird bio, Inc. (BLUE) Stock

bluebird bio, Inc. (NASDAQ:BLUE) insider David Davidson sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total value of $1,081,800.00. Following the completion of the sale, the insider now directly owns 21,977 shares of the company’s stock, valued at approximately $3,962,453.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of bluebird bio, Inc. (NASDAQ BLUE) traded down $2.65 during trading on Friday, reaching $177.10. The company had a trading volume of 599,100 shares, compared to its average volume of 536,000. The company has a market capitalization of $8,020.00, a price-to-earnings ratio of -25.26 and a beta of 2.08. bluebird bio, Inc. has a 1-year low of $63.10 and a 1-year high of $222.03.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business’s revenue was up 397.4% compared to the same quarter last year. During the same quarter last year, the business posted ($2.07) earnings per share. equities analysts forecast that bluebird bio, Inc. will post -6.72 EPS for the current fiscal year.

BLUE has been the subject of a number of research reports. Wedbush reissued an “outperform” rating and issued a $174.00 price objective (up previously from $135.00) on shares of bluebird bio in a research note on Thursday, November 2nd. Cantor Fitzgerald reissued a “sell” rating and issued a $39.00 price objective on shares of bluebird bio in a research note on Thursday, September 28th. Evercore ISI raised bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a research report on Monday, October 16th. BMO Capital Markets lifted their target price on bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research report on Monday, October 30th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $157.45.

A number of institutional investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in bluebird bio by 9.6% during the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares during the period. Capital Research Global Investors raised its stake in shares of bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares during the period. Baillie Gifford & Co. raised its stake in shares of bluebird bio by 3.8% in the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares during the period. Vanguard Group Inc. raised its stake in shares of bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares during the period. Finally, BlackRock Inc. raised its stake in shares of bluebird bio by 4.3% in the second quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares during the period.

TRADEMARK VIOLATION WARNING: “David Davidson Sells 6,000 Shares of bluebird bio, Inc. (BLUE) Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/05/david-davidson-sells-6000-shares-of-bluebird-bio-inc-blue-stock.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply